Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity
index (CAI) score and other evaluation indicators in pediatric patients with moderate to
severe ulcerative colitis after TA-650 administration of at a dose of 5 mg/kg at weeks 0, 2,
and 6, and then every 8 weeks at weeks 14 and 22. The safety and pharmacokinetics are also
evaluated.